DocumentRX-4720
Issued
Read3 min

Cretostimogene Cuts Bladder Cancer Relapse Risk 68% in Phase 3

CG Oncology's cretostimogene met its Phase 3 primary endpoint, cutting bladder cancer relapse risk 68% versus surveillance and setting up a second approval filing next year.

TAG K-6975 · 558 words on the filing

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial3534679 / pixabay

Summary of findings

  • Cretostimogene cut relative risk of relapse by 68% after 17 months of follow-up in a Phase 3 trial.
  • No severe or worse drug-related adverse events; no discontinuations due to side effects.
  • CG shares rose 12%, bringing market value near $8 billion after a $380 million 2024 IPO.
  • BCG-unresponsive filing expected early next year; the new setting has no approved therapy.
  • RBC's Timashev models up to $3.2 billion in peak annual U.S. sales by 2035.

Cretostimogene cut the relative risk of bladder cancer recurrence by 68% against standard surveillance in a Phase 3 trial, CG Oncology reported Monday, clearing the study's primary endpoint and moving the company toward a second approval filing next year.

The oncolytic virus therapy was tested in patients with intermediate-risk and high-grade non-muscle invasive bladder cancer following surgery. After 17 months of follow-up, treatment recipients relapsed at a rate 68% below the control arm, which received surveillance only. CG Oncology will present the full dataset at a medical meeting next month.

What does the safety profile show?

Investigators recorded no drug-related adverse events graded "severe" or worse, and no patient discontinued treatment because of side effects. The tolerability data track with what earlier testing of cretostimogene has shown. The company withheld finer detail on Monday; the medical-meeting presentation next month will carry the numbers that reviewers and competitors will scrutinize.

The market moved immediately. CG shares climbed 12%, lifting the company's market value close to $8 billion — more than double where it stood after a $380 million initial public offering in 2024.

Where does this fit in the bladder cancer pathway?

Non-muscle invasive bladder cancer confines tumor cells to the bladder's inner lining. Standard practice calls for the immunotherapy BCG after tumor resection, but BCG fails a substantial share of patients, and many responders relapse anyway. When those interventions run out, patients face radical cystectomy — surgical removal of the bladder.

CG Oncology has positioned cretostimogene, an oncolytic virus that infects and kills cancer cells while activating the immune system, as a potential "backbone" therapy usable across multiple treatment settings. The drug has now succeeded in two Phase 3 trials in two different settings, and the company is building cretostimogene into a two-indication franchise.

The first filing targets patients no longer responding to BCG. CG Oncology has pushed back that submission timeline more than once, but it now expects to complete the filing early next year. The results announced Monday will support a separate application next year in an intermediate-risk, post-surgery setting that currently has no approved therapeutic option at all.

How are analysts reading the data?

TD Cowen analyst Tyler Van Buren wrote that the 68% risk reduction is "exceptional" and tops the 30% to 40% range that management and investors had hoped the treatment would surpass. He also judged cretostimogene "likely the only agent" that will become available in both non-muscle invasive bladder cancer settings.

RBC Capital Markets analyst Leonid Timashev took a similar view of the headline number, with a caveat on what remains unseen. "Today's data clears even the most optimistic bars," Timashev said, while noting that the full dataset CG presents next month will be critical to "better understand" exactly how the drug performed.

Timashev projects cretostimogene could reach up to $3.2 billion in peak annual U.S. sales by 2035.

What does this change for the field?

For anyone running an NMIBC pipeline, the bar has moved. A 68% relapse-risk reduction in the intermediate-risk, post-resection setting leaves little room for marginal challengers, and the prospect of one agent spanning both the BCG-unresponsive and post-surgery settings consolidates the franchise logic around cretostimogene. The full dataset lands next month; the second filing follows next year.

via BioPharma Dive (Source)

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

22 articles

Linked filings

  1. V-5532
  2. T-7849
  3. C-4460
  4. T-8353
  5. P-6323

« Previous filing